: Moderna’s stock boosted by positive data from trial of melanoma treatment combined with Merck’s Keytruda

Moderna’s stock was on track for its biggest one-day gain in more than a year.

Previous post Outside the Box: Want great returns without great risk? It’s possible if you do these two things.
Next post : ‘Retirement security is under threat’: More people are raiding retirement savings to pay bills